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ABSTRACT
Introduction: The First Basal Insulin
Evaluation (FINE) Asia study was a
prospective, observational registry evaluating
basal insulin initiation in Asian patients with
type 2 diabetes mellitus inadequately controlled
by oral antihyperglycemic agents.
Methods: The objective of this post hoc
analysis was to observe and report the findings
from individual participating countries. The
primary endpoint was change in glycosylated
hemoglobin (HbA1c) from baseline to month 6
after basal insulin initiation. Secondary
endpoints included change in fasting blood
glucose (FBG), percent of patients achieving
target HbA1c and FBG levels, average insulin
doses, and hypoglycemic events.
Results: The study included 2921 patients from
11 Asian countries at baseline, 2679 (92%) of
whom had evaluable data. Following initiation
of basal insulin (neutral protamine Hagedorn
insulin, glargine, or detemir), there was a
significant (P\0.001) difference in HbA1c
reduction and proportions of patients meeting
HbA1c and FBG targets (\7% and\110 mg/dL,
respectively) across all country cohorts by
month 6. Glycemic control also varied greatly,
with 7.4% (Taiwan) to 71.5% (China) of
patients reaching target HbA1c\7% levels.
Mean (±standard deviation) insulin dose
increases over the 6-month period ranged
from 0.5 ± 3.1 U (Pakistan) to 6.0 ± 8.6 U
(Thailand). Hypoglycemia rates also varied,
with 7.1% (India) to 27.3% (China) of patients
experiencing one or more events.
Conclusions: Data from the FINE-Asia registry
study show widely varying degrees of baseline
comorbidities and glycemic control in patients
among the country cohorts observed. Countries
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with [9 years of diabetes prior to insulin
initiation had the lowest reductions in HbA1c
and proportions of patients achieving HbA1c
and FBG targets, suggesting that earlier basal
insulin initiation may afford better glycemic
control in these patients.
Funding: This study was funded by Sanofi.
Keywords: Asia; Basal insulin; Insulinization;
Type 2 diabetes
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a progressive
disease characterized by insulin resistance and
decline of b-cell function [1, 2]. Tight glycemic
control is one of the cornerstones of effective
management of T2DM, as it significantly reduces
the risk of microvascular complications and may
reduce the impact of macrovascular problems,
particularly when achieved early in the disease
course [3–5].
Based on clinical and experimental studies,
the International Diabetes Federation proposed a
preferred glycosylated hemoglobin (HbA1c)
target of B6.5% for the management of T2DM
[3–6]; experts from the American Diabetes
Association and the European Association for
the Study of Diabetes issued a statement
advocating HbA1c levels of \7.0%, with
stringency of control adapted according to
patient-specific features such as age, disease
duration, and comorbidities, among others [7].
This statement recognized that insulin can be an
effective componentofmanagement strategies to
achieve glycemic control, and early initiation of
insulin is recommended in patients not meeting
HbA1c targets. The benefits of insulin therapy and
the recommendations for its initiation in
treatment guidelines have been demonstrated
via observational studies and medical insurance
database analyses conducted in European and
NorthAmericancountries [8–10]. The translation
of this to the Asian experience, however, has not
specifically been reported. At the same time, the
prevalence of T2DM continues to increase at
higher rates among Asian countries than in other
regions [11].
Available evidence suggests that insulin
utilization in Asia has not markedly changed
over the past 10 years [12–14], despite changes in
treatment guidelines advocating the initiation
and intensification of therapy to reach HbA1c
goals. The objective of the First Basal Insulin
Evaluation (FINE)-Asia study was to provide
details on the real-world initial insulinization in
patients with T2DM across Asia, as well as to
determine the tolerability and efficacy of basal
insulin regimens in this region. This article
provides information from post hoc analysis of
the FINE-Asia study, which examined variations
in baseline characteristics and efficacy and safety
endpoints according to the country or region
from which patients were enrolled.
METHODS
FINE-Asia was a multinational, prospective,
observational study designed to assess the
initiation of basal insulin in insulin-naı¨ve
patients with T2DM in a real-world clinical
setting in Asia. Patients were enrolled from 195
centers/sites across 11 different Asian countries
(Bangladesh, China, Hong Kong, India,
Indonesia, Korea, Pakistan, Singapore, Taiwan,
Thailand, and Vietnam) [15].
Study Objectives
The FINE-Asia study was designed to evaluate
current clinical practice in the treatment of
Asian patients with T2DM with inadequate
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glycemic control on oral antidiabetic drugs
(OADs) who have been initiated on basal
insulin. The main objective of this post hoc
analysis was to examine the baseline
characteristics of the study population and to
report the findings of the study according to the
country or region from which patients were
enrolled. The primary efficacy endpoint was the
change in HbA1c from baseline to month 6 after
basal insulin initiation. Secondary endpoints
included change in fasting blood glucose (FBG)
from baseline to month 6, percent of patients
achieving target HbA1c and FBG levels, average
insulin doses, and hypoglycemic events.
Patients
From the centers/sites participating in this
registry study, male or female patients aged
C20 years with T2DM inadequately controlled
(HbA1c C 8%) by OADs, and who, in the
opinion of their treating physician, required
the initiation of a basal insulin, were eligible for
inclusion in the registry.
Patients who received premixed insulin at the
start of the registry period, who were prescribed
insulin shortly before the start of the registry
period (with the exception of acute rescue insulin
therapy), or women who were either pregnant or
of childbearing potential (not surgically sterile or
postmenopausal for less than 2 years) and were
not going to use a reliable contraceptive measure
for the duration of the studywere not included in
this registry. In addition, patients with known
hypersensitivity to insulin or any excipients of
marketed insulin were also excluded from the
study.
Study Treatment and Assessments
Basal insulin was initiated with or without
concomitant OADs, and no specific protocol
on the type of basal insulin or OADs
administered was recommended. The doses of
basal insulin were based on the
recommendation of locally approved package
inserts and individually adjusted by the treating
physicians based on individual patient profiles
(e.g., comorbidities, tolerability/preference,
etc.). Follow-up duration was 6 months; the
registry involved three main visits scheduled
according to physician routine practice, at
which point effectiveness and safety data were
collected (at inclusion, month 3 ± 7 days, and
month 6 ± 7 days). Each visit included standard
physical examinations (including body weight
and blood pressure) and assessments of HbA1c,
FBG and self-monitoring of blood glucose
(SMBG) profiles, adverse drug reactions
(ADRs), and hypoglycemic episodes. It was
recommended that patients perform SMBG
using their own glucose monitors by their
usual practice. In addition, SMBG was
recommended when mild to moderate
hypoglycemic events occurred. Safety was
evaluated using the ADRs reported during the
follow-up period, including all non-serious
ADRs (especially hypoglycemic events), serious
ADRs, overdoses, and changes in clinical and/or
laboratory data. Severe hypoglycemia was
defined as blood glucose (BG) \70 mg/dL
(3.9 mmol/L) and requiring assistance.
Statistics
Statistical analyses were based on patients with
HbA1c data at both baseline and 6 months. All
data were analyzed using SAS version 9.2
statistical software (SAS institute, Cary, NC)
and summary statistics (mean, median, range,
and standard deviation for continuous
variables, and number and percent for
categorical variables) were determined.
Student’s paired t test was used to compare
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parameters before and after the treatment
period, and qualitative variables and
between-group comparisons were analyzed
using Fisher’s exact probability test or
chi-square tests as appropriate. All statistical
tests were performed using two-tailed tests at a
5% level of significance.
Compliance with ethics guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
RESULTS
Baseline Characteristics of the Study
Population
The study included 2921 patients from 11 Asian
countries at baseline; 2679 patients with both
baseline and 6-month HbA1c values were
included in this post hoc analysis.
Demographic characteristics and insulin
regimen at baseline are shown in Table 1. Most
patients initiated insulin therapy with insulin
glargine. Mean (±standard deviation) insulin
dose at baseline ranged from 9.5 ± 3.4 U/day in
Thailand to 15.2 ± 6.3 U/day in Taiwan. Across
the countries/region cohorts examined, mean
duration of diabetes ranged from 6.3 ± 5.2 years
(China) to 11.5 ± 7.1 years (Taiwan), and
baseline HbA1c ranged from 9.4% ± 1.2%
(India) to 10.5 ± 1.9% (SE Asia). Mean baseline
HbA1c (10.5 ± 1.9%) and FBG (230 ± 69.0 mg/
dL [12.8 ± 3.8 mmol/L]) were highest in
patients from South-East Asia (group defined
in this study as Bangladesh, Hong Kong,
Indonesia, Singapore, and Vietnam). Patients
from Taiwan had the longest duration of OAD
use (11.1 ± 7.0 years; primarily sulfonylurea
and/or biguanides) and were among those
with the highest baseline HbA1c level
(10.2 ± 1.7%). Patients from China had the
shortest duration of OAD use (5.8 ± 5.2 years)
and were among those with the lowest baseline
HbA1c (9.4 ± 1.6%) and FBG (185 ± 47.2 mg/dL
[10.3 ± 2.6 mmol/L]) levels. In contrast to
patients from SE Asia (24.2 ± 3.8 kg/m2),
patients from Pakistan (27.9 ± 6.3 kg/m2) had
the highest body mass index. The prevalence of
diabetic neuropathy or nephropathy ranged
from 14.1% (SE Asia) to 39.2% (India),
coronary artery disease from 7.0% (Pakistan)
to 21.4% (China), and dyslipidemia from 48.8%
(China) to 84.4% (Thailand) (Table 2).
Efficacy and Safety by Country at 6
Months
After the addition of basal insulin therapy,
significant decreases in HbA1c (P\0.001) were
observed from baseline to month 6 for each
individual country/region, with decreases
differing significantly between country cohorts
(P\0.001), ranging from -1.3% in Taiwan to
-2.6% in China and Pakistan (Fig. 1; Table 3).
After basal insulin initiation, significant
reductions in FBG for each individual country
cohort were also observed (P\0.001). In
addition, increases in the proportion of
patients achieving FBG\110 mg/dL
(6.1 mmol/L) were observed at 6 months,
although these proportions varied significantly
(P\0.001 between each country/region).
Proportions (at 6 months) ranged from 24.7 to
27.6% among the patients in Taiwan, Korea,
South-East Asia, and Thailand, and from 43.7 to
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64.8% among those in India, China, and
Pakistan (Fig. 2).
Wide variations between the cohorts in
individual countries/regions were also
observed in terms of the proportion of patients
achieving HbA1c\7% at 6 months, with
percentages ranging from 7.4% (Taiwan) to
71.5% (China) (Table 3). These variations were
also observed with respect to mean insulin
dosing, where mean daily dose increases
ranged from 0.5 ± 3.1 U/day for the patients in
Pakistan to 6.0 ± 8.6 U/day in the Thailand
cohort (Table 3).
After basal insulin initiation, significant
differences were observed in the proportion of
patients experiencing at least one hypoglycemic
event during the 6 months of the study
(P\0.001), with the Indian cohort having the















Diabetic retinopathy* 26.9 19.6 30.6 19.9 19.1 30.1 25.4
Diabetic neuropathy* 35.3 39.2 22.5 38.4 38.6 21.5 33.4
Diabetic nephropathy* 24.5 14.5 20.3 15.0 14.1 23.8 36.8
Coronary artery disease* 21.4 16.9 8.9 7.0 13.3 13.1 11.8
Stroke* 6.4 1.4 5.2 9.2 5.8 2.9 5.4
Other diab. vascular disease* 7.5 2.1 0.7 2.7 1.1 1.9 1.9
Hypertension* 49.0 72.1 65.6 67.7 59.4 69.8 73.4
Dyslipidemia* 48.8 62.6 53.6 62.1 58.7 64.2 84.4
All values are % patients
SE Asia South-East Asia
* P\0.0001 between countries/regions for all characteristics
a Bangladesh, Hong Kong, Indonesia, Singapore, and Vietnam
Fig. 1 Mean (standard deviation) glycosylated hemoglobin (HbA1c) at baseline and month 6. *P\0.001 compared with
baseline. aSouth-East Asia: Bangladesh, Hong Kong, Indonesia, Singapore, and Vietnam. SD standard deviation
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lowest percentage (7.1%) and the Chinese
cohort the highest (27.3%).
DISCUSSION
The Asia–Pacific region comprises more than
half of the world’s population and has the
largest diabetes burden in the world, with
hypertension, dyslipidemia, and metabolic
syndrome also highly prevalent [16]. India,
China, and Pakistan make up three of the top
10 countries having the most people with
diabetes, while the prevalence of T2DM in
Thailand is 9.8%—double the number forecast
by the World Health Organization [17, 18]. An
increased risk of death associated with high
HbA1c, age, history of coronary artery disease,
and cerebrovascular disease has been reported
from the Thailand Diabetic Registry cohort [18].
As a result, establishing HbA1c goals and
treating patients in these countries, with the
intent of rapidly and effectively achieving target
HbA1c levels, is crucial to successful glycemic
control.
Data from this FINE-Asia study show widely
varying degrees of glycemic control in patients
with T2DM, depending on country of residence.
Of the country cohorts observed, the highest
percentage of patients reaching target HbA1c
levels of \7.0% at study end (71.5%) was
observed in Chinese patients. Along with
India, China had the joint lowest mean HbA1c
levels (9.4%) at baseline, yet only 43.0% of
Indian patients with T2DM reached target
HbA1c levels of\7.0% at study end. It should
be noted that Chinese patients had the shortest
duration of diabetes (6.3 years) and OAD use
(5.8 years) of any country studied, including
India. In line with findings from previous
studies [19], as well as the Chinese Guidelines
for Prevention and Treatment of Diabetes,
Chinese patients with T2DM appear to benefit
from earlier initiation of treatment. Rates of
hypoglycemia, however, were highest (27.3%)
in Chinese patients and lowest among those in
India (7.1%). Although hypoglycemia is a
well-reported side effect of insulin treatment
[20], these findings highlight the importance of
monitoring glucose levels upon initiation of
basal insulin treatment, particularly when an
early, aggressive approach to glycemic control is
undertaken. While the reasoning for the
disparity in hypoglycemia rates cannot be fully
elucidated, duration of diabetes (6.3 vs.
Fig. 2 Percentage of patients with a fasting blood glucose (FBG) level of\110 mg/dL at baseline and month 6. P\0.001
between countries. *P\0.001 compared with baseline. aBangladesh, Hong Kong, Indonesia, Singapore, and Vietnam
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9.8 years among the Chinese versus Indian
cohort, respectively), duration of OAD usage
(5.8 vs. 9.2 years), and neutral protamine
Hagedorn usage (37.5% vs. 5.0% of patients),
among other characteristics, are under
consideration for further analysis.
Study cohorts from Korea and Taiwan had
the longest duration of diabetes (10.7 and
11.5 years, respectively), as well as OAD use
duration (9.2 and 11.1 years); baseline HbA1c
levels were also among the highest of all the
countries analyzed. Interestingly, both
countries had the smallest change in HbA1c
and the lowest proportion of patients achieving
HbA1c and FBG goals at 6 months. In these
countries, patients did not receive insulin
treatment until much later in the course of
their disease, suggesting that earlier initiation of
insulin treatment may result in more favorable
glycemic control.
The concept of real-world clinical practice
observational studies provides an expanded
opportunity to observe and analyze
therapeutic management strategies outside of
more rigid, protocol-driven controlled clinical
trials [21]. This is particularly important in
diabetes, where both physician- and
patient-based decisions and practice can
impact outcomes. Multinational observational
studies such as A1chieve (NCT00869908) [22],
IMPROVE (NCT00659282) [23], PREDICTIVE
(NCT00659295) [24], and PRESENT [25],
among others, have utilized real-world clinical
practice as the basis for observing and
recommending management approach
adjustments to optimize glycemic control in
the context of insulin initiation. Many of these
studies, such as A1chieve and CREDIT [26], are
longer in duration and aim to analyze
multifactorial aspects of long-term impact of
treatments and treatment strategies. Our study,
not unlike other studies mentioned above, was
limited to 6 months’ duration. This was due to
the fact that the study goal was to observe
potential effects of insulin initiation; longer
duration of observation, while informative,
would potentially risk confounding the intent
of the study with longer-term management
adjustments.
As with the aforementioned observational
studies, there are limitations and considerations
that should be acknowledged. Lack of
randomization, predefined visits, or
protocol-driven care could potentially result in
variations between patients and countries with
respect to individual diabetes management.
Varied clinical practice between countries
should be considered when interpreting these
data. For example, in some Asian countries it is
not unusual for physicians to discontinue OAD
treatment when initiating basal insulin, either
for cost- or patient-related reasons; as such, this
may have influenced between-country
differences in glycemic control. In general,
country-specific approaches to insulin
initiation (initial dosing, patient education,
dietary behavior, procedural variation in
management), as well as choice of OAD, may
influence clinical response, yet it is important to
note that this is reflective of real-world clinical
practice, which was a key aspect of our study.
There is a lack of available information
regarding time of insulin administration,
SMBG, and concomitant medications, which
also may influence glycemic control. Since
HbA1c, FBG, and other clinical measurements
were performed in different laboratories/
hospitals and outside a rigid, protocol-driven
setting, inconsistencies/errors may be possible.
Glycemic management differences between
countries were directly observed, and other
country-based factors likely warrant
consideration as well. When considering basal
insulin choice, no patients in any of the other
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participating countries (with the exception of
0.7% of patients in India) were using insulin
detemir, except for 13.4% of patients in Taiwan.
Findings of recently published studies [27–29]
suggest that the use of insulin glargine is
associated with greater glycemic control than
insulin detemir at the same dose.
The study populations observed herein
represent a subset of patients with
unacceptably poor glycemic control (mean
HbA1c ranging from 9.4% to 10.5%). These
HbA1c levels would intuitively result in more
substantial reductions in the glycemic
endpoints observed in our study compared
with randomized clinical trials; nevertheless,
the HbA1c reductions observed in our study
(–1.27% to 2.64%) are not drastically higher
than those seen in the overall FINE-Asia
population, in other multinational
observational studies [8], or in randomized
controlled trials in patients initiating basal
insulin [30, 31].
The results of this prospective, observational,
registry-based study in these Asian countries
suggest that initiation of insulin therapy is
prolonged considerably in many Asian
countries, and that glycemic control remains
suboptimal in many patients. Given the
importance of T2DM to the health care of the
region, this is a notable concern. Duration of
diabetes prior to insulinization, comorbidities,
as well as baseline insulin choice and dosing
(both at initiation and throughout treatment),
varied significantly between countries, all of
which may have impacted the level of glycemic
control achieved and should be studied further.
CONCLUSION
Importantly enough, these data confirm that
local conditions—as reflected by the
country-based outcomes observed herein—may
play an important role in the pattern of care
and outcomes. Ultimately, these
country-specific findings support those from
the overall FINE-Asia study, suggesting that in
Asian patients with T2DM, initiation of basal
insulin earlier in the course of diabetes
treatment may be considered a factor for
better glycemic control.
ACKNOWLEDGMENTS
Sponsorship and article processing charges for
this study were funded by Sanofi. Editorial
support was provided by Albert M. Balkiewicz,
MSc (PPSI, Hackensack, NJ, USA), and Leigh
Prevost, MSc, (PPSI, Worthing, UK), and was
funded by Sanofi. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
manuscript, take responsibility for the integrity
of the work as a whole, and have given final
approval for the version to be published.
Disclosures. Linong Ji has no conflicts of
interest to disclose.
Shih-Tzer Tsai has been a consultant for Sanofi,
Takeda, and Eli Lilly, and has received hono-
raria for speaker services from Sanofi and Novo
Nordisk.
Jay Lin is a consultant for Sanofi.
Sanjiv Bhambani has been a consultant for and
received honoraria from Sanofi, Merck Sharpe &
Dohme, Bristol-Myers Squibb, and Novartis.
Compliance with ethics guidelines. All
procedures followed were in accordance with
the ethical standards of the responsible
committees on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
528 Diabetes Ther (2015) 6:519–530
2013. Informed consent was obtained from all
patients for being included in the study.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommer-
cial use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. American Diabetes Association. Diagnosis and
classification of diabetes mellitus. Diabetes Care.
2005;28(Suppl 1):S37–42.
2. Abdul-Ghani MA, Tripathy D, DeFronzo RA.
Contributions of beta-cell dysfunction and insulin
resistance to the pathogenesis of impaired glucose
tolerance and impaired fasting glucose. Diabetes
Care. 2006;29:1130–9.
3. The Diabetes Control and Complications Trial
Research Group. The effect of intensive treatment
of diabetes on the development and progression of
long-term complications in insulin-dependent
diabetes mellitus. N Engl J Med. 1993;329:977–86.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil
HA. 10-year follow-up of intensive glucose control
in type 2 diabetes. N Engl J Med. 2008;359:1577–89.
5. Stratton IM, Adler AI, Neil HA, et al. Association of
glycaemia with macrovascular and microvascular
complications of type 2 diabetes (UKPDS 35):
prospective observational study. BMJ.
2000;321:405–12.
6. International Diabetes Federation. IDF Clinical
Guidelines Task Force. Global guideline for Type 2
diabetes. International Diabetes Federation. http://
www.idf.org/global-guideline-type-2-diabetes-2005.
Accessed 3 Dec 2013.
7. Inzucchi SE, Bergenstal RM, Buse JB, et al.
Management of hyperglycemia in type 2 diabetes,
2015: a patient-centered approach: update to a
position statement of the American Diabetes
Assocation and the European Association for the
Study of Diabetes. Diabetes Care. 2015;38:140–9.
8. Liebl A, Breitscheidel L, Nicolay C, Happich M.
Direct costs and health-related resource utilisation
in the 6 months after insulin initiation in German
patients with type 2 diabetes mellitus in 2006:
INSTIGATE study. Curr Med Res Opin.
2008;24:2349–58.
9. Nichols GA, Gandra SR, Chiou CF, Anthony MS,
Alexander-Bridges M, Brown JB. Successes and
challenges of insulin therapy for type 2 diabetes
in a managed-care setting. Curr Med Res Opin.
2010;26:9–15.
10. Karter AJ, Moffet HH, Liu J, et al. Glycemic response
to newly initiated diabetes therapies. Am J Manag
Care. 2007;13:598–606.
11. International Diabetes Federation. IDF Diabetes
Atlas, 6th edn. Brussels, Belgium. International
Diabetes Federation. http://www.idf.org/
diabetesatlas. Accessed 3 Dec 2013.
12. Chan JC, Gagliardino JJ, Baik SH, et al. Multifaceted
determinants for achieving glycemic control: the
International Diabetes Management Practice Study
(IDMPS). Diabetes Care. 2009;32:227–33.
13. Mohamed M. An audit on diabetes management in
Asian patients treated by specialists: the
Diabcare-Asia 1998 and 2003 studies. Curr Med
Res Opin. 2008;24:507–14.
14. Shichiri M, Kishikawa H, Ohkubo Y, Wake N.
Long-term results of the Kumamoto Study on
optimal diabetes control in type 2 diabetic
patients. Diabetes Care. 2000;23(Suppl 2):B21–9.
15. Tsai ST, Pathan F, Ji L, et al. First insulinization with
basal insulin in patients with Type 2 diabetes in a
real-world setting in Asia. J Diabetes.
2011;3:208–16.
16. Tan DA. Changing disease trends in the
Asia–Pacific. Climacteric. 2011;14:529–34.
17. Ali MK, Narayan KM, Tandon N. Diabetes &
coronary heart disease: current perspectives.
Indian J Med Res. 2010;132:584–97.
18. Pratipanawatr T, Rawdaree P, Chetthakul T, et al.
Thailand Diabetic Registry cohort: predicting death
in Thai diabetic patients and causes of death. J Med
Assoc Thai. 2010;93(Suppl 3):S12–20.
19. Weng J, Li Y, Xu W, et al. Effect of intensive insulin
therapy on beta-cell function and glycaemic
control in patients with newly diagnosed type 2
diabetes: a multicentre randomised parallel-group
trial. Lancet. 2008;371:1753–60.
Diabetes Ther (2015) 6:519–530 529
20. Barendse S, Singh H, Frier BM, Speight J. The impact
of hypoglycaemia on quality of life and related
patient-reported outcomes in Type 2 diabetes: a
narrative review. Diabet Med. 2012;29:293–302.
21. Ligthelm RJ, Borzi V, Gumprecht J, Kawamori R,
Wenying Y, Valensi F. Importance of observational
studies in clinical practice. Clin Ther.
2007;29:1284–92.
22. Home PD, El Naggar N, Khamseh M,
Gonzalez-Galvez G, Shen C, et al. An
observational, non-interventional study of people
with diabetes beginning or changed to insulin
analogue therapy in non-Western countries: the
A1chieve study. Diabetes Res Clin Pract.
2011;94:352–63.
23. Valensi P, Benroubi M, Borzi V, Gumprecht J,
Kawamori R, et al. The IMPROVE study: a
multinational, observational study in type 2
diabetes: baseline characteristics from eight
national cohorts. Int J Clin Pract. 2008;62:1809–19.
24. Meneghini LF, Donhorst A, Sreenan S, the
PREDICTIVE Study Group. Once-daily insulin
detemir in a cohort of insulin-naive patients with
type 2 diabetes: a sub-analysis of the PREDICTIVE
study. Curr Med Res Opin. 2009;25:1029–35.
25. Khutsoane D, Sharma SK, Almustafa M, Jang HC,
Azar ST, et al. Biphasic insulin aspart 30 treatment
improves glycemic control in patients with type 2
diabetes in a clinical practice setting. Diabetes Obes
Metab. 2008;10:212–22.
26. Home PD, Dain MP, Freemantle N, Kawamori R,
Pfohl M, et al. Four-year evolution of insulin
regimens, glycaemic control, hypoglycaemia and
body weight after starting insulin therapy in type 2
diabetes across three continents. Diabetes Res Clin
Pract. 2015;108:350–9.
27. Eland I, Heintjes E, Houweling L, deGrooth R,
Veneman TF, Bouter KP. Insulin glargine versus
insulin detemir: glycemic control and insulin dose
in type 2 diabetes mellitus patients using a medical
record linkage system in The Netherlands.
J Diabetes Metab. 2011;2:165.
28. Rosenstock J, Davies M, Home PD, Larsen J, Koenen
C, Schernthaner G. A randomised, 52-week,
treat-to-target trial comparing insulin detemir
with insulin glargine when administered as
add-on to glucose-lowering drugs in insulin-naive
people with type 2 diabetes. Diabetologia.
2008;51:408–16.
29. Swinnen SG, Dain MP, Aronson R, et al. A 24-week,
randomized, treat-to-target trial comparing
initiation of insulin glargine once-daily with
insulin detemir twice-daily in patients with type 2
diabetes inadequately controlled on oral
glucose-lowering drugs. Diabetes Care.
2010;33:1176–8.
30. Buse JB, Wolffenbuttel BH, Herman WH, et al.
DURAbility of basal versus lispro mix 75/25 insulin
efficacy (DURABLE) trial 24-week results: safety and
efficacy of insulin lispro mix 75/25 versus insulin
glargine added to oral antihyperglycemic drugs in
patients with type 2 diabetes. Diabetes Care.
2009;32:1007–13.
31. Owens DR, Traylor L, Dain MP, Landgraf W.
Efficacy and safety of basal insulin glargine 12 and
24 weeks after initiation in persons with type 2
diabetes: a pooled analysis of data from treatment
arms of 15 treat-to-target randomised controlled
trials. Diabetes Res Clin Pract. 2015;106:264–74.
530 Diabetes Ther (2015) 6:519–530
